Currently, there are 78.07M common shares owned by the public and among those 68.67M shares have been available to trade.
The company’s stock has a 5-day price change of 7.73% and 17.10% over the past three months. ACCD shares are trading -66.36% year to date (YTD), with the 12-month market performance down to -50.73% lower. It has a 12-month low price of $3.35 and touched a high of $15.36 over the same period. ACCD has an average intraday trading volume of 1.17 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.23%, 0.64%, and -46.73% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Accolade Inc (NASDAQ: ACCD) shares accounts for 69.99% of the company’s 78.07M shares outstanding.
It has a market capitalization of $323.24M and a beta (3y monthly) value of 1.97. The earnings-per-share (ttm) stands at -$1.16. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.49% over the week and 5.40% over the month.
Earnings per share for the fiscal year are expected to increase by 24.59%, and 7.88% over the next financial year. EPS should grow at an annualized rate of -0.90% over the next five years, compared to -2.85% over the past 5-year period.
Looking at the support for the ACCD, a number of firms have released research notes about the stock. Needham stated their Buy rating for the stock in a research note on June 28, 2024, with the firm’s price target at $13-$8. Leerink Partners coverage for the Accolade Inc (ACCD) stock in a research note released on February 26, 2024 offered a Outperform rating with a price target of $16. DA Davidson was of a view on January 17, 2024 that the stock is Neutral, while Barclays gave the stock Equal Weight rating on January 03, 2024, issuing a price target of $13. BofA Securities on their part issued Buy rating on May 24, 2023.
